Overview
Mitochondria are often called the powerhouse of cells, and their ability to produce energy efficiently directly impacts how we feel, exercise, and function daily. When mitochondrial dysfunction occurs—whether due to genetic conditions, aging, or injury—the result is often persistent fatigue, reduced exercise capacity, and diminished quality of life.
SS-31 (also known as elamipretide) is a synthetic tetrapeptide designed to target and stabilize mitochondria at the cellular level. Unlike broad-spectrum antioxidants or general supplements, SS-31 works through a highly specific mechanism: it binds directly to cardiolipin, a critical phospholipid found only in the inner mitochondrial membrane. By doing so, it preserves the architecture of the electron transport chain and enhances the efficiency of ATP production—the primary currency of cellular energy.
The scientific interest in SS-31 for energy has grown substantially, driven by clinical trials in patients with inherited mitochondrial disorders and other conditions characterized by energy metabolism dysfunction. This article reviews what the current research reveals about SS-31's effects on energy production and exercise capacity.
How SS-31 Affects Energy
SS-31's mechanism for enhancing energy production is rooted in fundamental mitochondrial biology. The compound crosses cell membranes and accumulates selectively in the inner mitochondrial membrane, where it binds with high affinity to cardiolipin—a unique phospholipid that anchors critical respiratory chain complexes.
Stabilizing the Electron Transport Chain
The electron transport chain is the machinery responsible for converting nutrients into ATP through oxidative phosphorylation. SS-31 stabilizes the organization of this chain by preventing cardiolipin peroxidation and maintaining the structural integrity of respiratory supercomplexes. This allows electrons to flow more efficiently from NADH and FADH₂ through complexes I through IV, ultimately driving ATP synthase and maximizing energy yield per molecule of substrate oxidized.
Reducing Mitochondrial Stress
Beyond its structural role, SS-31 also reduces reactive oxygen species (ROS) production within mitochondria. When the electron transport chain operates efficiently, fewer electrons escape and generate damaging free radicals. This dual action—improved efficiency and reduced oxidative damage—creates a synergistic benefit: more ATP produced with less cellular stress.
Restoring Membrane Potential
Mitochondrial membrane potential is the electrochemical gradient across the inner membrane that drives ATP production. SS-31's cardiolipin-stabilizing action helps restore and maintain this critical gradient, which often deteriorates in disease states or with aging.
What the Research Shows
Human clinical trial evidence for SS-31 and energy comes primarily from studies in patients with inherited mitochondrial disorders, particularly those with Barth syndrome and primary mitochondrial myopathy. These populations experience severe energy metabolism dysfunction and are ideal for evaluating whether SS-31 can meaningfully improve energy status and exercise capacity.
Barth Syndrome: Long-Term Sustained Benefits
Barth syndrome is a rare X-linked disorder characterized by defective cardiolipin remodeling, directly compromising mitochondrial function. The TAZPOWER trial and its long-term extension evaluated elamipretide in this population.
In the open-label extension phase, Barth syndrome patients receiving elamipretide (40 mg daily via subcutaneous injection) demonstrated a cumulative 96.1-meter improvement in the 6-minute walk test over 168 weeks. This metric is clinically significant: the 6-minute walk test is a validated measure of exercise capacity and functional energy status. The improvement persisted over the extended follow-up period, suggesting sustained benefit rather than a temporary response.
Importantly, fatigue scores—a direct patient-reported measure of energy availability—also improved significantly in this cohort. For a rare genetic disorder where few effective treatments exist, sustained improvements in both objective exercise capacity and subjective energy perception represent meaningful progress.
Primary Mitochondrial Myopathy: Mixed but Promising Results
Primary mitochondrial myopathy encompasses a heterogeneous group of genetic disorders affecting mitochondrial function. The MMPOWER-3 trial was the largest and most rigorous test of elamipretide in this population, enrolling 218 patients.
The overall trial population did not meet its primary endpoints: the 6-minute walk test distance and fatigue scores did not show statistically significant improvement with elamipretide versus placebo. This negative finding was disappointing and highlighted the complexity of treating genetically diverse mitochondrial disorders with a single therapeutic approach.
However, post-hoc genetic analysis revealed critical nuance. Patients with specific nDNA (nuclear DNA) variants affecting the mtDNA replisome machinery—a subgroup comprising approximately 25% of the trial cohort—showed a 25.2 ± 8.7-meter improvement on the 6-minute walk test with elamipretide versus 2.0 ± 8.6 meters with placebo, a result trending toward statistical significance. This suggests that SS-31 may be particularly effective in specific genetic subgroups characterized by defective mitochondrial DNA replication or repair, rather than in all mitochondrial myopathy patients indiscriminately.
Additionally, fatigue scores showed statistically significant improvements in MMPOWER-2, an earlier subcutaneous dosing trial, where patients receiving 40 mg daily demonstrated significant reductions in fatigue severity.
Cellular and Tissue-Level Evidence
Supporting the clinical observations, laboratory research demonstrates SS-31's direct impact on energy production. In aged human bone marrow stem cells, SS-31 increased ATP production by 35% and reduced reactive oxygen species by 40% in in vitro conditions. While this doesn't directly translate to human efficacy, it demonstrates the compound's capacity to enhance mitochondrial bioenergetics at the cellular level.
In human cardiac tissue obtained from myectomy patients with hypertrophic cardiomyopathy, pre-incubation with elamipretide boosted NADH-linked respiration—a direct measure of electron transport chain efficiency. This finding, derived from 59 patients' tissue samples, provides evidence that SS-31 can enhance oxidative phosphorylation capacity in human cardiac mitochondria ex vivo.
Animal Model Consistency
Animal studies consistently support SS-31's energy-enhancing effects. In cancer cachexia models—a condition of severe muscle wasting and energy depletion—SS-31 prevented reduction of glycolytic myofiber area and rescued intracellular ATP levels. While benefits were transient (observed at day 21 before disease progression at day 28), the capacity to preserve or restore ATP in severely compromised tissue is noteworthy.